schwab has rated it as "A" grade
JNJ taking out Synthes certainly opens the door for that. Stryker and Zimmer could look to add market share. Wright management could be seen as vulnerable being CEO-less at the moment. Even if Wright goes for 3x Sales ($40/sh, $1.6B), that would be a huge jump from current $16/sh price.Stryker has nearly 3B in cash, 1B in debt. Zimmer about 1B in cash, 1B in debt.Stryker could buy Wright for cash using their checkbook.